[go: up one dir, main page]

WO2018136625A3 - Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss - Google Patents

Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss Download PDF

Info

Publication number
WO2018136625A3
WO2018136625A3 PCT/US2018/014223 US2018014223W WO2018136625A3 WO 2018136625 A3 WO2018136625 A3 WO 2018136625A3 US 2018014223 W US2018014223 W US 2018014223W WO 2018136625 A3 WO2018136625 A3 WO 2018136625A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating diseases
compositions
diseases characterized
synapse loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/014223
Other languages
French (fr)
Other versions
WO2018136625A2 (en
Inventor
Michael C. Carroll
Allison Rosen BIALAS
Jessy PRESUMEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of WO2018136625A2 publication Critical patent/WO2018136625A2/en
Publication of WO2018136625A3 publication Critical patent/WO2018136625A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

As described below, the invention provides compositions and methods for identifying and treating diseases characterized by reactive microglia and synapse loss (e.g., central nervous system (CNS) lupus, Alzheimer's disease).
PCT/US2018/014223 2017-01-20 2018-01-18 Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss Ceased WO2018136625A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448840P 2017-01-20 2017-01-20
US62/448,840 2017-01-20

Publications (2)

Publication Number Publication Date
WO2018136625A2 WO2018136625A2 (en) 2018-07-26
WO2018136625A3 true WO2018136625A3 (en) 2018-09-07

Family

ID=62908308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/014223 Ceased WO2018136625A2 (en) 2017-01-20 2018-01-18 Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss

Country Status (1)

Country Link
WO (1) WO2018136625A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029601A1 (en) * 2004-06-21 2006-02-09 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
WO2012068636A1 (en) * 2010-11-26 2012-05-31 The University Of Melbourne Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
US20150147336A1 (en) * 2006-12-06 2015-05-28 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers and uses thereof
US20150290207A1 (en) * 2014-03-19 2015-10-15 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029601A1 (en) * 2004-06-21 2006-02-09 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
US20150147336A1 (en) * 2006-12-06 2015-05-28 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers and uses thereof
WO2012068636A1 (en) * 2010-11-26 2012-05-31 The University Of Melbourne Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
US20150290207A1 (en) * 2014-03-19 2015-10-15 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARUCH ET AL.: "Aging-induced type I interferon signaling at the choroid plexus negatively affects brain function", SCIENCE, vol. 346, no. 6205, 3 October 2014 (2014-10-03), pages 89 - 93, XP055211098 *
BIALAS ET AL.: "I-07: IFNAR Signalling Promotes Microglia Dysfunction in SLE", LUPUS SCIENCE AND MEDICINE, vol. 3, no. 1, 31 August 2016 (2016-08-31), pages A37, XP055553037 *
BIALAS ET AL.: "Microglia-dependent synapse loss in type I interferon-mediated lupus", NATURE, vol. 465, 14 June 2017 (2017-06-14), pages 539 - 543, XP055553049 *
DECZKOWSKA ET AL.: "Mef2C restrains microglial Inflammatory Response and is Lost in Brain Ageing in an IFN-I-Dependent Manner", NATURE COMMUNICATIONS, vol. 8, 1 September 2017 (2017-09-01), pages 1 - 13, XP055553080 *
MINTER ET AL.: "Deletion of the Type-1 Interferon Receptor in APPSWE/PS1DELTAE9 Mice Preserves Cognitive Function and Alters Glial Phenotype", ACTA NEUROPATHOLOGICA COMMUNICATIONS, vol. 4, no. 72, 11 July 2016 (2016-07-11), pages 1 - 23, XP055553065 *
MORIGUCHI ET AL.: "Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling", ONCOLMMUNOLOGY, vol. 5, no. 12, 14 October 2016 (2016-10-14), pages 1 - 8, XP055553072 *
WANG ET AL.: "Systemic Interferon-a Regulates Interferon-Stimulated Genes in the Central Nervous System", MOLECULAR PSYCHIATRY, vol. 13, 8 May 2007 (2007-05-08), pages 293 - 301, XP055553044 *

Also Published As

Publication number Publication date
WO2018136625A2 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
WO2020102646A3 (en) Inhibitors of arg1 and/or arg2
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
PT3873604T (en) Methods for treating alzheimer's disease
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2017214170A3 (en) Baff-r antibodies and uses thereof
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017218949A3 (en) Peptidomimetic macrocycles and uses thereof
WO2014152965A3 (en) Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
HK1246810A1 (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders
HK1250171A1 (en) Method for detecting genomic variations using circularised mate-pair library and shotgun sequencing
WO2017066712A3 (en) Modulators of telomere disease
MX2022004759A (en) Methods and compositions for treating liver diseases and disorders.
WO2018183692A8 (en) Vectors and compositions for treating hemoglobinopathies
WO2015166045A3 (en) Alkaline phosphatase for use in the treatment of neurodegenerative and neuronal diseases
MX378940B (en) NEURODEGENERATIVE DISORDERS.
WO2019087130A3 (en) Method of inhibiting angiogenesis
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
WO2017066796A3 (en) Modulators of telomere disease
EP3979985A4 (en) Compositions and methods for treating central nervous system disorders
WO2018140850A3 (en) T cells derived from umbilical cord blood
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
WO2015109318A3 (en) Therapeutic methods
WO2016103042A8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17
PH12021550213A1 (en) Methods for treating neurodegenerative disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18741254

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18741254

Country of ref document: EP

Kind code of ref document: A2